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Nosocomial pneumonia is associated with a high rate of mortality, particularly in ventilated patients in the intensive care 
unit (ICU). There have recently been a number of advances in the diagnosis, prevention and treatment of ventilator- 
associated pneumonia (VAP), as well as in the understanding of its etiology and pathophysiology. New diagnostic 
techniques, such as protected specimen brushing (PSB) and bronchoalveolar lavage (BAL) have been developed and 
assessed. Potential sources of pathogens have been investigated with molecular techniques. 
Progress in prevention has been made, with new measures, including putting intubated patients in a semi-recumbent 
position with continuous aspiration of subglottic secretions or selecting stress-ulcer prophylactic regimens which do not 
modify the gastric pH. Meta-analysis has shown that selective digestive decontamination (SDD) reduces the risk of 
developing ventilator-associated pneumonia and possibly mortality. Empirical treatment before culture results depends on 
various factors including the severity of the symptoms and the associated risk factors, but more importantly, the time of 
onset of pneumonia. Early-onset VAP (less than 4 days after admission) is likely to be caused by pathogens which originate 
in the oropharyngeal cavity (Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae), whereas 
aerobic, multi-resistant, Gram-negative bacilli are less likely unless there are predisposing risk factors. Late-onset VAP is 
more likely to be caused by Gram-negative bacilli or S. aureus and may involve Pseudomonas aeruginosa and 
Acinetobacter spp. 
Diagnostic work-up and antimicrobial treatment adapted to the individual patient with VAP is important and even 
crucial in patients with late-onset VAP and in patients with early-onset VAP and risk factors. Empirical treatment should be 
started after having collected adequate samples and should be modified according to microbiological results once they 
are available. Monotherapy with a p-lactam@-lactamase-inhibitor or a second- or third-generation cephalosporin is 
appropriate for empiric treatment of early-onset VAP with no risk factors which may alter the spectrum or susceptibility of 
microorganisms. A quinolone may be used in combination with clindamycin to ensure optimal coverage of S. aureus and 
anerobes, which are listed as potential pathogens. A third-generation cephalosporin may be chosen in areas where 
resistant pneumococci are frequently encountered. 
In the case of late-onset pneumonia,. or early-onset pneumonia with risk factors, the j3-lactam should have anti- 
pseudomonal activity (broad-spectrum penicillins or third-generation cephalosporins with antipseudomonal activity, 
fourth-generation cephalosporins, carbapenems). A fluoroquinolone plus clindamycin could be used in patients with 
penicillin allergy. A fourth-generation cephalosporin or carbapenem would also cover the most probable pathogens, such 
as Gram-negative bacilli (even those with inducible p-lactamases), and would ensure a better coverage for S. aureus than 
a third-generation cephalosporin. In hospitals where methicillin-resistant S. aureus is a problem, these agents should be 
combined with a glycopeptide. 
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INTRODUCTION 
Nosocomial pneumonia is the second most frequent 
hospital-acquired infection and is associated with high 
morbidity, mortality and increased hospital cost [l]. 
Nosocomial pneumonia occurs in 0.6-1%) of hospital 
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admissions and 7-44% of ventilated patients in the 
intensive care unit (ICU). Overall, it accounts for 
13-18% of all nosocomial infections, prolongs hospital 
stay by 7-10 days and is associated with a crude 
mortality of 20-60% and an attributable rnortality (the 
percentage of deaths which would not have occurred 
in the absence of pneumonia) of approximately 30%. 
In the ICU, pneumonia accounts for a higher 
proportion of nosocomial infections than in the 
hospital as a whole (35-45% in ventilated patients). 
Although the crude mortality is higher (40-80%) in 
the ICU, the attributable mortality in ventilated 
patients (27%) is similar to that seen in the hospital 
overall [2]. Nosocomial pneumonia is independently 
associated with death in ICU patients (Table l),  
although some recent studies have produced 
conflicting results [3,4]. 
In one of these studies, the predictors of mortality 
were examined in two populations of patients in the 
ICU, namely, those who survived and those who 
died. Nosocomial pneumonia was shown to be a 
significant factor associated with increased mortality, 
with an odds ratio of 2.08, similar to that of 
nosocomial bacteremia [3].  
If the mortality rate in ventilated patients is 
examined in more detail, it can be seen that different 
niortality rates may be attributable to different 
causative organisms. For example, Pseudomonas spp. 
and Acinetobacter spp. may be responsible for a 
mortality rate of up to 43% and even > 70% [2]. An 
effective strategy for the prevention of nosocomial 
infections in the ICU should significantly reduce 
mortality, but to assess potential strategies, it is 
essential to achieve a consistent diagnosis. 
DIAGNOSIS 
All studies regarding epidemiology, pathophysiology, 
risk factors, treatment, prognosis and prevention of 
pneumonia are hampered by the same problem - the 
difficulty in diagnosing pneumonia. Criteria used 
clinically to define nosocomial pneumonia include 
fever, new or progressive pulmonary infiltrate on 
X-rays, leukocytosis, purulent bronchial secretions 
and a tracheal aspirate Gram’s stain showing > 25 
leukocytes and < 10 squamous epithelial cells (a sign 
of sample contamination) per low-power field, 
associated with recovery of a potential pathogen [5]. 
Fever and infiltrate, however, are by no means specific 
for pneumonia. In the case of mechanically ventilated 
patients in particular, there are many other alternatives 
which need to be considered. Fibroproliferation of 
late adult respiratory distress syndrome (ARDS), 
pulmonary embolism atelectasis, drug reactions, 
congestive heart failure and pulmonary hemorrhage all 
show similar clinical signs and may mimic pneumonia. 
The presence of microorganisms in a tracheobronchial 
specimen may represent colonization or infection. 
Thus, efforts have been made to develop appropriate 
diagnostic testing, including changes in plasma 
concentration of C-reactive protein [6] or changes in 
serum concentration of procalcitonin [7] to determine 
whether the patient has pneumonia, to identifj the 
pathogen and to help define the best therapeutic 
regimen. Lung specimens taken for histology and 
culture are considered to be the ‘gold standard’ in 
the diagnosis of pneumonia. The  criteria for 
histopathologic diagnosis of pneumonia include the 
presence of neutrophilic infiltration of the terminal 
bronchioles and of the alveoli, which may be filled 
with neutrophils, fibrinous exudates and cellular 
debris (resulting from lung necrosis) which may be 
seen by Gram’s stain [8]. For certain microorganisms, 
specific methods should be used. The etiological 
diagnosis is established by identification of the 
pathogen(s), generally by culture. There are major 
problems, however, with the gold standard method. 
Firstly, the invasive nature of the technique means 
that these specimens cannot be obtained for most 
episodes of pneumonia; secondly, if there is a lung 
biopsy or autopsy, it may not be obtained at the same 
time as the pneumonic episode, making it difficult to 
Table 1 Variables independently associated with death in ICU patients 
Variable Odds ratio P 
APACHE I1 score 
No. of dysfunctional organs 
Nosoconiial pneumonia 
Nosocomial bacteremia 
Fatal underlying disease 
Adnlission from other ICU 
1.08 
1.54 
2.08 
2.51 
1.76 
1.30 
<0.001 
<0.001 
<0.001 
<0.001 
4 . 0 0 1  
0.04 
~ ~ ~ ~~~ 
From Fagon et al. 1996 [3 ] .  With permission of the American Medical Association. 
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be sure that the findings relate to a particular clinical 
episode of pneumonia. Moreover, the empiric use of 
antibiotics to treat the episode may invalidate direct 
examination or culture results. In ventilated patients 
lung 1iistolobT is usually only used in post-mortem 
studies. 
Given this problem of diagnosis, improved, less 
iiivasive methods have been developed. The most 
important of these are listed in Table 2 [4,9-321. It  
should be borne in mind that sensitivity and specificity 
are always measured in relation to another method 
which will, in itself, have advantages and disadvantages. 
Thresholds have evolved from various studies, for 
which the sensitivity and specificity vary, depending 
on how tlie criteria were balanced. Results from a recent 
meta-analysis suggest that the use of a predetermined 
threshold concentration of bacteria for either protected 
specimen brushing (PSB) or bronchoallveolar lavage 
(BAL) may riot be appropriate in all clinical settings 
and that incorporating the clinical :likelihood of 
pneumonia into the evaluation could significantly 
improve the sensitivity and specificity of these tests [33]. 
It can be seen from Table 2 that a n  indisputable 
diagnosis cannot be reached using any of- the methods. 
Nevertheless, it is generally accepted i;hat PSB and 
BAL are currently the most accurate methods for 
diagnosing pneumonia. Although the sensitivity and 
specificity of these methods are highly variable, a 
recent study has shown sensitivities of 82% and 
91% and specificities of 89% and 78% for PSB and 
BAL, respectively, compared with histologic and 
microbiologic post-mortem lung specimens, in the 
diagnosis of pneumonia [34]. However, other post- 
mortem studies have found lower sensitivities and/or 
specificities [4,35,36]. 
Both of these methods can be performed either 
through a bronchoscope or  blindly, using an 
endobronchial catheter. PSB involves the passage of a 
catheter into the distal airways and the extrusion of a 
small brush (protected inside the catheter by a 
biodegradable plug) for the recovery of secretions. 
BAL requires sequential instillation and aspiration of a 
physiological solution into a lung subsegnient through 
a catheter or a bronchoscope wedged in an airway. 
Mini-BAL (mBAL) refers to BAL using a smaller 
volume ofsolution (l(320 mL, rather than lO(3200 mL) 
instilled distally. 
The specimen volume retrieved with PSB is much 
smaller (0.01-0.001 mL) than with BAL and the area 
of lung sampled is also smaller, such that the threshold 
for quantitative samples is usually higher for BAL 
(> lo4 CFU/mL) than for PSB (> lo3 CFU/mL). 
However, the risk of contamination is less for PSB 
and mBAL (protected) than for BAL. One advantage 
of BAL, however, is that it allows the sampling of 
enough material for direct examination by Gram’s 
stain and some studies have shown that the presence 
of visible intracellular bacteria is a good predictor of 
ventdator-associated pneumonia PAP)  [37]. In addition, 
direct examination may help in the choice of initial 
antibiotic treatment. 
PSB and BAL have their own problems. For 
example, when an examination was repeated using I’SB 
on the same patient twice, although 100% qualitative 
reproducibility was recorded, a 24-25% quantitative 
discordance in tlie numbers of niicroorganisms 
recovered was reported between the first and second 
examinations (16,381. This may have been caused by 
peripheral wedging of the brush, but means that for 
PSB, no quantitative threshold exists which absolutely 
separates patients with and without pneumonia [25], 
Also, many patients received antibiotics and it has 
been shown by Meduri et al. [39] that this can reduce 
the number of true positive results obtained by PSB 
quantitative culture from 77% in untreated patients, to 
60% in those on antibiotic therapy. Recent studies 
Table 2 Value of various methods for the nllcrobiological diagnosis of ventilator-associated pneumonia in patients with c h n i c ~ l  and radiologcal 
signs compatible with pneumonia 
Thrcshold Sensitivity Specificity Correct Diagnosis Refs 
(cfu/mL) (%) (“X) (%I) 
Endotrachcal aspirate 
qualitative 57-88 33-14 
quantitative 105- 1 Oh 67-9 1 92-59 
Non bronchoscopic distal specimens 101-104 61-100 100-66 
(naAL,  PSB) 
BAL B 104 72-1 00 100-69 
Protected BAL t 104 82-92 97-83 
Protected \pecinien brushing 2 103 64-100 95-60 
9-13 
72-83 14-10 
70-100 4,i 0 3 - 2 2  
69-90 23-26 
72-03 27-29 
84-96 30-32 
Adapted from Griffin JJ et al. [51. With permission from Medical Clinics of North America. 
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have shown that quantitative analysis of endotracheal 
aspirates appears to be of reasonable diagnostic value 
[40,41]. Investigations should be performed before 
introducing or changing antibiotic therapy [42]. If 
possible, antibiotic therapy should be discontinued for 
48 h before PSB or BAL are used [42]. Increased levels 
of endotoxin has been shown to predict the prescence 
of Gram-negative pneumonia [43,44]. New diagnostic 
methods, such as the measure of procalcitonin levels in 
bronchial secretions are being investigated clinically [7]. 
In summary, despite the improvement in diagnostic 
methods, not all patients are correctly diagnosed as 
having pneumonia, with both under- and over- 
diagnosis being a problem. Better communication is 
necessary to achieve optimal diagnosis. 
ETIOLOGY AND PATHOPHYSIOLOGY 
Table 3 shows the causative organisms of pneumonia 
in ventilated patients. The spectrum vanes according to 
regional differences, underlying disease and previous 
antibiotic treatment. In many cases knowledge of the 
sources of these organisms helps in understanding the 
pathophysiology of the infection. Often, the source is 
endogenous, but the organism may also come from the 
environment, from other patients or from hospital staff 
(Figure 1). Devices and other equipment are currently 
less of a problem, now that they are recognized sources 
of infection and aseptic handling and equipment have 
improved. Cross-infection from other patients and staff 
may be minimized, provided that human resources are 
adequate and that motivation is high. 
Episodes occurring within the first few days after 
intubation (early-onset pneumonia: 4 days has been 
proposed as an arbitrary time point) [45] are mostly 
caused by bacteria of the normal oropharyngeal flora. 
If certain factors are present, such as prior antibiotic 
therapy, prolonged hospitalization or special host factors, 
there may be a different spectrum of microorganisms 
with different antibiotic susceptibilities, and this has 
important diagnostic and therapeutic implications. 
Episodes occurring after 4 days of intubation (late-onset 
pneumonia) are mostly due to Gram-negative bacilli 
or S. aureus. 
The oropharyngeal flora as a source of infection 
Microorganisms colonizing the trachea and the lung 
rarely originate from the hematogenous route, but are 
derived mainly from oropharyngeal flora or from the 
gut [46,47]. Infection ofthe respiratory tract will depend 
on the numbers and virulence of the inoculated 
organisms balanced against the efficiency of mechanical, 
cellular and humoral lung defence mechanisms. Soon 
after patients enter an ICU, their oropharynx becomes 
colonized with Gram-negative bacilli [48] and this is 
associated with a higher rate of pneumonia compared 
with patients who have no colonization. For example, 
in a study of 213 intensive care patients, 23% of those 
with oropharyngeal colonization developed nosocomial 
pneumonia, whereas pneumonia was seen in only 3.3% 
of non-colonized patients [49]. There are, of course, a 
number of other contributory risk factors and these 
will be addressed later. 
It is not known precisely why the oropharynx 
becomes colonized with Gram-negative bacilli, but one 
important cause is thought to be stress, which leads to 
the secretion of enzymes that alter receptors at the 
surface of the pharyngeal cells. These alterations of 
pharyngeal cells promote adhesion by Gram-negative 
organisms. Johaiison et al. [SO] showed that brief 
exposure of buccal epithelial cells to trypsin increased 
the adherence of Pseudomonas aevuginosa ten-fold as 
compared to cells from non-colonized patients. This 
phenomenon has been recently discussed [47]. 
Table 3 Microorganisms causing ventilator-associated pneumonia 
Early-onset pneumonia Late-onset pneumonia Other 
Streptococcus pneumoniae Pseudomonas aenrginosa 
Haemophilus influenzae Enterobacter spp. 
Murawella catarrhalis Acinetubacter spp, 
Staphylococcus aureus K/ebsiella pneumoniae 
Aerobic Gram-negative bacillia Serratia marcescens 
Escherichia coli 
Other Gram-negative bacilli 
Staphylococcur aureusb 
Anerobic bacteria< 
Legionella pneumophila 
Influenza A and B 
Respiratory syncitial vims 
Fungi 
a h  patients with nsk factors. 
blncluchng methidin-resistant S aureus 
CFrom [46] 
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Environment Devices Enteral 
Other patients Nutrition 
Direct 
Contact 
Staff - 
Duodenum 
Patient's flora 
and urogenital tracts) 
c 
Distant site 
of infection 
c 
Lower respiratory tract - -1 
Air 
Ventilator-circuit 
J. - Pneumonia 
Figure 1 Routes of infection in ventilator-associated pneumonia 
Organisms colonizing the oropharynx of The stomach a s  a source of pathogen - .  
ventilated patients are often found subsequently in the 
trachea via microaspiration. One study showed that if 
a dye (Evans blue) was applied to the tongue, it could 
be detected subsequently in the tracheal aspirate, 
despite the fact that the trachea was obstructed by an 
endotracheal tube. This was noted in 56% of patients 
with a high pressure balloon and 20% ofpatients with 
a low pressure balloon [51]. The average time 
between instillation of Evans blue and the first positive 
test of the aspirate was 14 hours. 
In ventilated patients, there may also be an accumu- 
lation of secretion in the subglottic area, above the cuff 
of the balloon, which could be a reservoir of bacteria 
and increase the spread of organisms via microaspiration. 
Radiolabelled studies haye found bacterial biofilms 
on the surface of tracheal tubes [52,53]. In one study 
[53], 73% of tubes were found to contain biofilms 
positive for bacteria and 29% were positive for aerobic 
Gram-negative bacilli, with high bacterial counts (up 
to lo5 CFU/mL). When these tubes were examined 
more closely, cracks could be seen which appeared to 
be ideal niches for bacterial colonization. The bacteria 
may then be dislodged on an intermittent basis, gving 
them access to the tracheal tree in high inoculum, and 
this could trigger a pneumonic episode. However, the 
exact role of these observations are not yet clear. 
A study was performed in 24 patients, 13 on mechanical 
ventilation and 11 ventilating spontaneously, in which 
a radiolabelled marker (technetium-99m) was instilled 
into the stomach via a nasogastnc tube [54]. Two hours 
later, gamma radiation in the esophagus and bronchial 
aspirate was measured. Radiation was detected in the 
esophagus of 69% of patients on mechanical ventilation 
and 91% of patients spontaneously ventilating, and in 
the tracheal aspirate of 38% of patients on mechanical 
aspiration and 45% of patients spontaneously ventilating. 
From a bacteriologcal point of view, studies [55-621 
have found various percentages of retrograde tracheal 
colonization f?om the stomach and these are summarized 
in Table 4. These represent minimal percentages, 
based on the demonstration of a temporal sequence 
between the isolation of the same microorganisms in 
the stomach and, subsequently, in the trachea. 
In the study performed by Inglis et al. in 1993 
[62], sequential specimens were taken from intubated 
patients, one being obtained from the stomach and 
another from the trachea. The time between the two 
isolations was noted and it was seen that, on some 
occasions, there was a simultaneous occurrence of the 
organisms at both sites, but on > 50% of occasions 
[33,42], isolation from the stomach occurred (up to 16 
days) before the same organisms were isolated from the 
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Table 4 Studies dcrnonstrating retrograde tracheal colonization from the stomach (minimal estimate) 
~~~ 
Ketrograde Ketrogradc 
colonized L~lO~llZdtlOil colonization 
Ref no Number of Trachca and 
patients ctomach tracheal trachcd 
(4 (4 (4 (Xj 
Atherton (1978) 55 10 6 3 30 
du Moulin (1982) 56 60 17 1 1  18 
Goularte (1986) 57 39 11 4 1 0 
Daqchner (1988) 58 142 45 38 
Krusser (1989) 59 40 10 I 3 
Prod'hom (1990)a 60 151 48 0 6 
Pugin (1991) 61 52 22 15 29 
Inglis (1993)a 62 100 11 0 6 
aRetrograde colonization confirmed by molecular typing [62] 
trachea, suggesting that these organisms may have come 
from the stomach. Bonten et al., however, did not 
report any biological sequence of events [63]. Analysis 
of bilirubin suggested that bacteria even came from 
the duodenum. In a study by Prod'hom et al., 19/29 
episodes of late-onset pneumonia were due to Gram- 
negative bacilli, of which 16 (84%) involved bacteria 
which were colonizing the stomach before pneumonia 
developed as proved by molecular typing [64]. 
The stomach is normally highly acidic, but the pH 
can be increased both by drugs and by 'exocrine failure', 
which often occurs in Ventilated patients. As soon as 
the stomach pH increases above pH 4, it allows the 
growth of bacteria, especially Gram-negative bacilli. 
In a classical study published by Driks et al. [65], it was 
shown that patients receiving a stress-ulcer prophylactic 
treatment which did not alter the stomach pH were 
less often colonized in the stomach than patients being 
treated with an antacid or H2 blockers. 
Prod'hom, using molecular methods, showed that 
in Gram-negative pneumonia, the same organism was 
isolated from three sites of the same patient: the 
pharynx, the tracheal tube aspirate and the stomach. 
However, different strains were identified in all but 
two of the patients [64]. The data suggest that cross- 
infection was infrequent during this study and that 
bacteria causing infection were most likely to be part 
of the endogenous flora. 
Stress-ulcer prophylaxis 
Prod'hom also investigated the incidence of 
nosocomial pneumonia in 244 ventilated patients 
randomized to receive three types of anti-ulcer 
prophylaxis; antacid, the H2 antagonist ranitidine, or 
sucralfate [64]. The treatment received was shown to 
influence the median gastric pH of the patients, with 
patients on sucralfate having lower median values. 
Also, patients receiving sucralfate had a reduced 
frequency of gastric colonization in general and of 
gastric colonization with high bacterial counts (above 
lo5 CFU/mL). There was less late-onset pneumonia 
as a whole and less late-onset pneumonia caused by 
Gram-negative bacilli in the sucralfate-treated group 
than in patients treated with antacid or ranitidine. All 
of the pneurnonic episodes were observed in patients 
with high gastric pH, irrcspective of prophylaxis. It  
has been shown that sucralfate has some antimicrobial 
activity in its own right [MI, as well as anti-adhesive 
properties for microorganisms [67] and these factors 
may have contributed to this result. 
Most, but not all studirs which have addressed the 
role of various anti-stress ulcer prophylactic regimens 
have found that medications which increase the gastric 
pH are associated with an increased risk of pneumonia 
(Figure 2) [64]. These conflicting results are due to 
different patient populations (e.g. some studies have 
included ventilated and non-ventilated patients), 
insufficient sample size, or other methodological 
problems. In the late 198Os, Langer et al. 145,711 
suggested that pneumonia in ventilated patients is caused 
by different pathophysiologic mechanisms and by 
different microorganisms according to the timing of 
onset: early or late. In the study by Prod'hom already 
mentioned, the importance of this distinction on the 
result of anti-ulcer prophylactic regimens was 
investigated (Figure 3) [65,68-70,72-771. There was no 
effect of the type of anti-ulcer treatnient on the 
frequency of early-onset pneunionia, siiice this most 
probably originated from the oropharyngeal flora, which 
is unlikely to be affected by the anti-ulcer treatnient. 
The incidence of late-onset pneumonia, on the other 
hand, occurring after at least 4 days of intubation, wa7 
higher in the antacid and ranitidine-treated patient 
groups than in the sucralfate-treated group [68,73]. 
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Late 
onset 
Early 
onset 
Antacid 
n =  83 
Ranitidine 
n = 8 3  
Sucralfate 
n = 8 3  
0 4 8 12 16 
Days after intubation 
Figure 2 Effect of anti-ulcer prophylaxis on the incidence on pneumonia. With permission of Annals of Intcmal Medicine 1641. 
50 1 
W 
l rn  
Figure 3 Summary of reported cases of nosocornial pneumonia in mechanically-ventilated patients randomized to  <trCss 
bleeding prophylaxis with sucralfate (m) versus antacids (0) and H, blockers (0) or H2 blockers alone ( 
Craven et al. [72]. Prevention and control of nosocotnial infections. Willianis & Wilkins (1990). 
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Despite numerous studies addressing the choice of 
anti-stress ulcer prophylaxis, controversy persists as to 
whether or not sucralfate should be preferred to other 
regimens [69]. I n  a large meta-analysis sucralfate was 
found to be associated with a lower incidence of 
nosocomial pneumonia when conipared with antacids 
(OR 0.80 CL 0.56-1.15) and H2 receptor antagonists 
Selective digestive decontamination (SDD) is a 
controversial preventive nieasure [79]. It involves the 
use of oral, intestinal aiid often systemic antibiotics to 
eliminate all potential pathogeiis from the upper 
respiratory and gastrointestinal tracts. The use of SDD 
reduced thc incidence of pneumonia in a rneta-analysis 
carried out by the Selective Decontamination of the 
Digestive Tract Trialists’ Collaborative Group on 22 
randonllzed, controlled studies, evaluating approximately 
4,000 patients 1801. This nieta-arialysis showed that, 
although a significant reduction in the incidence of 
pneunionia/respiratory tract infection was seen in 
treated patients (OR 0.37 93% CL 0.31-0.43), the 
valuc of the coninion odds ratio for the overall mortality 
(OR 0.90 95% CL 0.79-1.04) suggested a t  best a 
moderate treatment effect. Better results in the reduction 
of mortality were found only if trials that conipared 
topical SDD plus early systemic antimicrobial treatment 
or placebo (OR 0.80 95% CL 0.67-0.97) were included. 
A3 there were large variations in the case mix, the 
sevciity and the SDD protocols, no firm coiiclusions 
can be drawn regarding the effect of SDD on niortality 
in ventilated patients. 
An important probleni with SDD is the potential 
for selection of antibiotic-resistaiit organisms 1811. 
Further investigation is required to more clearly 
(OR 0.77 C L  0.60-1.01) [78]. 
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identify the patients who could benefit from such an 
approach (821. 
PREVENTION 
Risk factors and associated preventive measures are 
surnniarized in Table 5. Some risk Eictors, such AS age 
(> 60 years), pulmonary disease, organ hilure, coma, 
gr o s s asp ira t i o 11, c i gar e t t c sin o ki 11 g , di a b e t e s , 
hypotension, alcoholism, diseases of the central nervous 
system, chronic obstructive lung disease, azotemia and 
respiratoiy failure are patient-related [ 11 aiid thus 
difficult to modify. Other risk factors are dependent 
on drug prescription. The stress-ulcer prophylaxis 
regimen has been mentioned, but the use of certain 
other drug arc also risk factors. Sedatives, corticosteroids 
and cytotoxic agents niay impair host defences. 
Antibiotic prophylaxis or treatment given prior to 
an episode of nosocomial pneumonia niay select for 
resistance and thus reduce therapeutic options. 
Endotracheal prophylactic gentarnicin was shown to 
be ineffective in preventing pneumonia and associated 
with the occurrence of gentamicin-resistant bacteria 
Effective preventive measures have been 
demonstrated in several studies [84]. Two studies have 
suggested that removal of subglottal secretions, using 
either a specifically designed endotracheal tube or a 
catheter, may decrease the risk of pneumonia 164,851. 
I n  the study by Valles et al., patients with continuous 
subglottic aspiration were less likely to develop 
pneumonia than those without subglottic aspiration 1851. 
The incidence ratc of VAP was 19.9 episodes/1000 
ventilator days in patients undergoing continuous 
(831. 
Table 5 Risk factors for ventilator-associated pneumonia and principles of prevention 
Risk Factor Prevention 
Host 
0 age > 60 yexrs 
pulinonary disease 
organ failure, coma 
gross aspiration 
Medical 
0 dui-ation of meclianical vcntilaaoii 
route of intubation 
0 rcintubation 
cross infection 
0 equipment 
0 oropharyngeal aspiration 
0 gastric pH and colonization 
0 gastric tnicroaspiration 
0 prior antibiotics 
primary prevention 
device rcnioval as ~ o o n  as possible 
prefer oral intubation 
avoid sclf extubation/reintubation 
ascptic care, standard precautions, isolation 
appropriate maintenance, disinfection 
aspiration o f  subglottic secretions 
prefer mcralfate to H, blockcrs/antacid 
semi-upright position 
proper use of antibiotics 
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aspiration and 39.6 episodes/? 000 ventilator days in 
the coiitrol group. The difference caused by a 
significant reduction iii tlie number of infections due 
to Gramii-positive cocci and H .  ir$irerrzoc in those 
receiving continuous aspiration (p < 0.03). New tubes 
x c  currently bciiig introduced which allow aspiration 
011 J continuous basis, although these tubes do have 
problems in their own right, such as ~:ontaiiiination 
and blockage of tlie luinen. 
Aiiotlicr recommendation is that both endotracheal 
and gastric tubes are inserted orally, rather than nasally. 
Kouby et al. [Xh] sliowcd the incidcnct of sinusitis to 
be linked to nasal placemelit. Moreovrr, nosoconiial 
piieuiiioiiia occurred sigiiificaii tly iiiort frequently in 
patients with maxillary sinusitis (67%) than in those 
without (43%) (p = 0.002). These results have been 
confirmed in another study 1871. 
A simple i i~cas~ire  to partially prevent esophageal 
reflux is to put the patient in a semi-rccumbeiit position, 
which has been sliowii to decrease the recovery rate 
of identical niicroorga~iisnis in the storiiacli, pharynx 
and trachea (32'%,), con~pared with patients in the supine 
position (68'%1). However, this is not feasible for all 
veiitildted patients ISXI. 
The incidence of pneuinonia is iiicreased if the 
ventilator circuit is inanipulatcd frequently and it is 
now reconimeiidcd to change it only evt-iy 72 hours or  
longer. Some recent studies suggest that it can be safely 
maintained for up to 7 days 1891. Cortdensatc in the 
tubing cai i  also be a reservoir of pathogens and should 
be drained away from the patient; heat and moisture 
exchangers might avoid tlie problem of condensation 
a n d  prevent colonization, thus perrnithg the use of 
the same circuit for a longer period of tinic. 
Many pathogens, such as P. ncrtlginosu and S .  ( I C ~ I T I ~ S ,  
survive well in the external environnieiit. Handliiig 
of devices and equipment should therefore be 
minimal. Aseptic technique and good hygiene, with 
frequent hand washing or  gloves for staff, isolation of 
patients with resistant pathogens and appropriate 
disinfection of equipnient can decrease environmental 
and cross-contaiiiiiiation. 
Mal~ititrition is a known risk factor for nosocomial 
pneunionia a i i d  has led to the use of nutritional support 
in hospitalized patients. There is no clear evidence 
that nutritional support reduces the risk of pneunioiiia, 
however, and care iiiust be taken regarding preparation, 
handling, route and voluiiie of feeding. Enteral 
nutrition niay stimulate the intestinal rnucosa and the 
immune system 1901, but any increase in gastric pH 
and volume could increase the number of potential 
pathogens in the stomach 1631. When possible, the tube 
should preferably be inserted beyond the stomach. 
EMPlRlC TREATMENT 
Appropriate diagnostic iiiicrobiologic'il procedures 
should be performed prior to the initiation o f  
treatment. Although a number of recent advcuices 
have been made in the diagiiosis, prevention and 
treatment of nosoconiial pneunionici, controversic~ 
still remain and a standardized managcnient approach 
docs not yet exist, mainly because of diagnostic 
problems. The clinical and radiologiccil signs of 
pneunionia caii be associated with a number of c;iiiscs, 
particularly in ventilated patients in thc ICU, and thc 
way  in which these are interpreted differs bctwccti 
physicians. For example, if a p t ien t  presents with 
lung infiltrate on X-ray, fever and raised whitc 
blood cell count, in most casc-s Iic wil l  receive a n  
enipiric course of antibiotic treatment. If, howevcr, 
there is no iinprovement aftrr 48 hours and the 
diagnostic tests (e.g. PSI3 or BAL) do no t  suggest a 
bacterial etiology, sonic physicians \vould suspciid 
antibiotic therapy and obsen-c tlie paticnt. Other 
physicians may prefer to continue a i l  tihiotic therapy 
and increase the dosage o r  modifi. the reginicii, 
suspecting the presence of a more resimnt or unusual 
pathogen which w x  not detected. I n  order t o  guide 
physicians, various recoiii~iic~idationc have heel1 
issued. Thew are based on a good uncierstanding of 
the etiopatliopliysi[)lo~~ and of risk factors. I t  is 
iniportant to stress that therapeutic cipproaclics vary 
according to the type of patient. Only nosocomial 
pneumonia in ventilated patients is considered in the 
present article. 
Early- and late-onset p i i ~ t i ~ n o i i i ~ ~  n ventilated 
patients have different bacterial etiology. For cxaniple, 
early-onset pneunioriia is likely to be c'iused by 
pathogens which are norni,il inli~ibitants of the 
oropharyngeal cavity, such as S. prrc~rn iorr inr~ ,  which 
c'aiises 5-10% of infections, H m ~ i z ~ y ~ ~ i i / i ~ ~  i ~ ! j ' / w t ~ ~ ,  
responsible for 546 of infections, o r  mixed flora, 
including ancrobes. S. U U ~ B M S  is dso '1 frequent cause of 
early-onset pneumonia. Conversely, aerobic Gram- 
negative bacilli, which arc responsible for at least 60(% 
of cases of pneumonia, are more likcly to be involved 
in late-onset piicuinonia. S. O I I Y ~ Y I S  also accounts for 
20-25% of the episodes in  late-onset pncmionia. 
Pathogens which are more likely to arise from 
exogenous sources, such as P.  ncriiyirrosn, i l c i r i c d m t w  
spp. and ~iicthicilliii-resistant S .  nurcwx, Lire also usually 
involved in late-onset pneumonic episodes. The 
differences in likely causative organisins, depending 
on the time of onset of tlie pneumonic episode, 
should be borne in niind w-lien choosing enipiric 
therapy for these infections. It is also very iinportant 
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to take into account the epidemiology and antibiotic 
susceptibility pattern of each institution. 
Patients with early-onset VAP and patients with 
no risk factors can be treated initially with agents such 
as p-lactams plus 0-lactamase inhibitors or second- or 
third-generation cephalosporins (Table 6). The choice of 
a third-generation cephalosporin in this situation may be 
justified by cost consideration in certain countries, such 
as the USA. For patients with late-onset pneumonia, 
or early-onset pneumonia plus associated risk factors, 
such as prior antibiotics, recent hospitalization or a severe 
underlying condition, a broader-spectrum antibiotic is 
recommended, such as broad-spectrum penicillin or 
thrd-generation cephalosporin, with anti-pseudomonal 
activity (including broad-spectrum p-lactam/p-lactamase 
inhibitors), or a carbapenem. A fourth-generation 
cephalosporin, such as cefpirome or cefepime as single 
agent may be considered. An alternative therapy for 
patients who cannot be treated with p-lactam antibiotics 
is the use of an intravenous fluoroquinolone. 
Vancomycin may be added for initial therapy in hospitals 
where there is a high prevalence of methicdhn-resistant 
staphylococci and anti-anerobic compounds added 
when anerobes are felt to play a predominant role. 
In a recent consensus of the American Thoracic 
Society, two treatment schemes were recommended 
in this situation [l]. These are based on the severity of 
the infection, the timing of occurrence of pneumonia 
(early- versus late-onset) and the presence of risk factors. 
The main difference from our recommendations is the 
use of an aminoglycoside or fluoroquinolone in 
combination with a p-lactam. One study has shown 
no difference in the success rate between treatment 
with imipenem alone and imipenem plus netilmicin 
in patients with nosocomial pneumonia and sepsis 
[91]. It has been suggested, however, that the presence 
of an aminoglycoside in severe cases may improve the 
activity of p-lactam antibiotics which are less potent 
than imipenem. For certain pathogens, such as 
Enterobactev and Pseudomonas spp. and in severe situations, 
combination therapy may be superior to monotherapy 
Whichever treatment scheme is used, a p-lactam 
agent is generally included unless the patient is allergic 
to penicillin. This may be a p-lactam@-lactamase 
inhibitor combination, a second- or third-generation 
cephalosporin or a carbapenem. Considering the 
etiology of nosocomial pneumonia and the in vitro 
activity of various p-lactam antibiotics, fourth-generation 
cephalosporins, such as cefpirome or cefepime, are 
worthy of consideration as alternatives to the p-lactam 
antibiotics currently used. These compounds have 
excellent Gram-positive activity, covering penicillin- 
resistant pneumococci and methicillin-susceptible 
S .  aureus, as well as an increased stability and lower 
affinity for inducible Gram-negative p-lactamases as 
compared to third-generation cephalosporins [92]. 
Although there is not yet a large amount of clinical 
data available on the efficacy of fourth-generation 
cephalosporins in nosocomial pneumonia, the 
Cefpirome Study Group reported on 91 patients with 
community-acquired or nosocomial pneumonia who 
received cefpirome intravenously [93]. Successhl clinical 
and bacteriological results were obtained in > 90% of 
patients. The authors concluded that cefpirome was 
an effective empiric treatment for moderate-to-severe 
pneumonia in hospitalized patients. However, difficult 
pathogens, such as Enterobacter cloacae and P. aevuginosa, 
were isolated in only a minority of patients. Although 
P.  aevuginosa is probably covered adequately by 
P11. 
Table 6 Suggested initial empiric therapy of ventilator-associated pneumonia 
Pneumonia Antimicrobial treatment” 
Early-onsct, no risk factors p-lactam/p-lactamase inhibitorb 
Second- or thirdc-generation cephalosporin 
Early-onset, risk factors, 
Late-onset d ~ k  Broad-spectrum p-lactani/p-lactamase inhibitor“ 
p-lactam anti-pseudomonal spectrum 
Fourth-generation cephalosporin 
Carbapenem 
Fluoroquinolone (iv) 
aTo be adapted to microbiological data for the patient and institution. 
bThe combination of amoxicillin/clavulanic acid is supenor to anipicillin/sulbactam against pneumococci. 
‘In sonie countries, third-generation cephalosporins are particularly cost-effective. 
%Some authorities would recommend the addition of an aminoglycoside in severe cases. 
CGlycopeptide to be added according to local epidemiology of methicillin-resistant staphylococci. 
fMetronidazole or clindamycin to be added when anti-anerobe coverage is indicated. 
rRisk factors (e.g. including prior antibiotic treatment) for alteration of the spectrum or susceptibility of microorganisms. 
“Ticarcillidclavulanic acid, piperacillidtazobactam. 
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cefpirome while awaiting microbiological results, other 
agents with improved activity against this organism 
should be selected when P. aevcrginosa is isolated. 
A larger and more recent multicenter study 
compared the efficacy and safety of cefpirome and 
cefiazidime, either as monotherapy or in combination, 
with an aminoglycoside or metronidazole in the empiric 
treatment of 400 patients with nosocomial and 
community-acquired pneumonia in the ICU [94]. 
Clinical failure rates at the end of treatment were 34% 
vs 36% for cefpirome bid and ceftazidime tid, 
respectively, with no difference in outcome between 
monotherapy and combination therapy. In a non- 
comparative study, a satisfactory clinical response was 
obtained in 89% of patients receiving cefkpime bid [95]. 
Based on these studies, it can be assumed that fourth- 
generation cephalosporins are good alternatives to 
other broad-spectrum antibiotics for the treatment of 
nosocomial pneumonia. 
CON CLU SI 0 N S  
Nosoconllal pneumonia in ventilated patients is caused 
by a combination of factors resulting in a variety of 
etiologies. Precise microbiological diagnosis requires the 
appropriate critical use of invasive methods and close 
collaboration between clinicians and microbiologists. 
Understanding the pathogenesis and epidemiology of 
infection allows the clinician not only to define optimal 
preventive strategies, but also to decide upon optimal 
empiric therapy while awaiting microbiologcal results. 
DISCUSSION 
Prof. P.  Francioli: The exact burden of VA 
pneumonia in terms of morbidity and rnortality is not 
well established and have been addressed specifically 
in only a few studies. 
Prof. A. Torres: Several papers have indicated that 
the attributable niortality of VA pneumonia is 
approximately 30%. However, this is controversial. 
For example, Papazian et al. recently suggested that the 
initial nlicrobiologcal diagnosis might be a confounding 
factor. In  this study, attributable mortality was not due 
to VA pneumonia in itself but mostly related to the 
appropriateness of the initial empiric therapy. 
Prof. P. Francioli: Differences in the results of 
various studies might also be related 1.0 the method 
used for the diaposis of pneurnonix Hence, the 
diagnosis is the cornerstone of any study addressing 
the problem of VA pneumonia, but is hampered by 
the lack of a method which would be both highly 
sensitive and specific, and readily available. At the 
present time, lung specimens taken for microbiological 
and histological examination are considered to be the 
‘gold standard’ technique. 
Prof. A. Torres: There are problems associated with 
the ‘gold standard technique. In particular, these studies 
are almost exclusively post-mortem studies, and it is 
unlikely that a technique based on obtaining lung 
specimens is going to be widely available in clinical 
situation. 
Prof. W. Wilson: Given the problems of the ‘gold 
standard’ for the diagnosis of pneumonia, are there any 
recommendations regarding which technique is the 
most appropriate? 
Prof. J. Chastre: Several different techniques are 
available, but all of them are associated with 
methodological problems, and it remains unclear 
which is the most appropriate method. At this stage, 
BAL and PSB are considered to  be the most accurate 
methods. 
Prof. P. Francioli: Recent studies have suggested 
quantitative culture of endotracheal aspirates might be 
as accurate as more invasive methods. 
Prof. J. Chastre: Yes, and this needs further 
investigation. It is important to emphasize that 
appropriate sampling should be obtained prior to 
initiation of antimicrobial treatment, when possible. 
Prof. P. Francioli: I n  addition, appropriate samples 
should be obtained before any change in  the antibiotic 
treatment. 
Prof. P. Shah: It should be mentioned that new 
methods for diagnosing pneumonia have been and are 
being investigated, such as measurement of the 
endotoxin or procalcitonine levels in bronchal secretions. 
These methods have shown promising results. 
Prof. P. Francioli: In recent years, progress in the 
prevention of VA pneumonia has been made. 
Environmental sources of infection have certainly been 
reduced by the systematic use of adequate hygienic 
measures. New devices such as cndotracheal tubes 
allowing the aspiration of subglottic secretions have 
been developed. 
Prof. A. Torres: Undoubtedly, these tubes appear to 
bring some progress. However. they Iiavc their ou7n 
problems, such as contamination or blockage of the 
lumen. 
Moreover, studies were performed with prototypes 
and should probably be confirmed with the tubes 
which are now becoming available on the market. 
Prof. P.  Francioli: Two preventive measures arc still 
controversial: the choice of anti-stress ulcer prophylaxis 
regimen and the selective digcstive decontaminatioii 
(SDD). Regarding the anti-stress ulcer prophylaxis 
regimen, meta-analysis of the existing studies suggest 
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that regmen which elevate the gastric pH might be 
associated with increased incidence of VA pneumonia. 
However, the most controversial measure is probably 
SDD. 
Dr. M. Langer: It is true that this measure is the most 
controversial, but this is more of an emotional than 
rational reaction. Hence, the data are very clear: there 
is no doubt that certain SDD regimens decrease the 
incidence of VA pneumonia. This is also confirmed 
by several meta-analysis. However, it is also true that 
no firm conclusion can be drawn regarding the effect 
of SDD on mortality. More studies are needed to 
identify which patients might benefit most from such 
a measure. The issue is emotional and controversial 
because of the risk of selecting resistant microorganisms. 
This risk might depend on the type of regimen used. 
More work is needed in this area. 
Prof. P. Shah: At the present time, one indication 
for the use of SDD might be an epidemic situation 
related to a multi-resistant microorganisms. 
Prof. P. Francioli: Regarding the initial empirical 
treatment of VA pneumonia, it is important to 
distinguish early-onset pneumonia from late-onset 
pneumonia. 
Prof. J. Acar: Could you clan@ this concept ? 
Prof. M. Langer: We were the first to describe the 
difference in the spectrum of microorpsms responsible 
for a pneumonia in relation to the time of onset of 
infection. In an Italian multicenter study, approximately 
50% of the pneumonic episodes developed within the 
first 4 days after intubation. Most were due to bacteria 
recovered from the normal oropharyngal flora. In 
contrast, patients developing pneumonia at a later 
stage were most likely to be infected with Gram 
negative bacilli. The same was true for patients with 
early onset pneumonia and risk factors, such as patients 
with prior antibiotic treatment. This was confirmed 
by several other studies and fits with our present 
knowledge of the pathogenesis of VA pneumonia. 
This distinction is important for the treatment. Thus, 
initial empirical treatment of pneumonia will depend 
on the time of onset of the episode and the presence 
or not of risk factors. 
Prof. J. Acar: Anerobes are also responsible for 
episodes of early-onset pneumonia. 
Prof. M. Langer: This is particularly true when gross 
aspiration has occurred. In addition, some studies have 
showed that anerobes can be recovered in approximately 
30% of pneumonic episodes. The exact role of this 
anerobes remain to be determined. 
Prof. P. Francioli: In patients with early-onset 
pneumonia and no risk factors, the first line regimen 
would be a p-lactam/p-lactamase inhibitor combination 
or a second- generation cephalosporin. Should a third- 
generation cephalosporin (without antipseudomonal 
activity) also be recommended €or this indication? 
Prof. W. Wilson: Second-generation cephalosporin 
are unavailable in certain countries and are also more 
expensive than third-generation cephalosporins in 
many countries. This is true for the USA. Thus, third- 
generation cephalosporins should be included 
as alternative to second-generation cephalosporins 
in the treatment of early-onset pneumonia with no 
risk factors. Regarding the p-lactam@-lactamase 
inhibitor combinations, it should be mentioned that 
amoxicillin-clavulanate is more active than ampicillin- 
sulbactam against penicillin resistant pneumococci. 
However, parented amoxicillin-clavulanate is not 
available in the USA, where only ampicillin-sulbactam 
is commercialized. 
Prof. J. Acar: There are some data suggesting that 
nosocomial Gram-negative pneumonia may also occur 
after the first few days of intubation. 
Prof. A. Torres: This is true, but these patients 
generally have risk factors, mostly prior antibiotic 
treatment or a severe underlying disease. 
Prof. P. Francioli: Initial empirical therapy in these 
patients should be identical to that of patients with 
late-onset pneumonia. 
Prof. J, Chastre: We should emphasize that, whatever 
patient is considered, appropriate microbiological 
sampling should be performed before the initiation of 
empirical treatment. Moreover, empirical treatment 
should be adapted according to the microbiological 
results and the clinical response. 
Prof. P. Francioli: For late-onset pneumonia or for 
patients with early onset-pneumonia and risk factors, 
a broader coverage is needed as compared to early-onset 
pneumonia. This is due to the fact that the distribution 
of microorganisms is different and involves certain 
Gram-negative microorganisms such as the Pseudomonas, 
Enterobacter or Acinetobacter which are usually resistant 
to the antibiotics recommended for early-onset 
pneumonia. A broad-spectrum p-lactam with anti- 
pseudomonal activity or a carbapenem are the drugs of 
choice. In penicillin allergic patients, a fluoroquinolone 
combined with or without an anti-anerobe compound 
is an alternative. 
Prof. J. Acar: Third-generation cephalosporins with 
anti-pseudomonal activity carry the risk of encountering 
Enterobacteriacae producing inducible cephalosporinase 
and selecting for such resistant microorganisms. One 
should probably select agents such as cefpirome or 
cefepime, which may avoid the selection of resistant 
microorganisms. 
Prof. W. Wilson: The American Thoracic Society 
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recommends combination therapy for empirical 
treatment of VA pneumonia, mainly the combination 
of a broad-spectrum p-lactam (eg. a third-generation 
cephalosporin) and an aminoglycoside. 
Prof. P. Francioli: This is still a controversial issue. 
Some studies have demonstrated that adding gentamiciii 
or netilmicin to imipenem has not improved the 
outcome of patients with nosocomial pneumonia. 
Whether or not this is true for agents other than 
carbapenenu remains to be determined. However, some 
subgroups of patients might benefit from combination 
therapy, in particular those with Pseudornorzas, 
Enterobactcr or Acinetobacter infections. For the other 
cases, a carbapenem, a fourth-generation cephalosponn 
or piperacillin-tazobactam are probably :adequate first- 
line empiric therapy for late-onset pneumonia. 
Prof. P. Shah: A combination therapy should 
probably be envisioned in the initial regimen of all 
severe cases. 
Prof. P. Francioli: Glycopeptides should be added 
to the treatment regimen according to the local 
epidemiology of MRSA infections. This, is particularly 
true if Gram-strain of the bronchial sp'xirnen shows 
Gram-positive cocci. 
Dr. M. Langer: It should be remembered that S. aureus 
is also a frequent pathogen encountered in early-onset 
pneumonia. However, in this instance., S. au~eus  has 
been community-acquired and is generally susceptible 
to methicillin. 
Prof. P. Francioli: This discussion illustrates that there 
are still many open questions in the field of ventilator- 
associated pneumonia. 
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